

Group II, claims 18 and 28, drawn to a process for stabilizing a gene formulation by adding at least one saccharide and/or at least one non-hydrophobic amino acid and/or at least one organic acid; and

Group III, claims 19 and 29, drawn to a method for gene therapy by using the gene formulation set forth above.

**For the purpose of examination of the present application, Applicants elect, with traverse, Group I, claims 1-17 and 20-27.**

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact John W. Bailey (Reg. No. 32,881) at the telephone number below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 

John W. Bailey, #32,881

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

JWB/end  
0020-4769P